Rapid antimicrobial resistance detection for early directed therapies against infectious diseases
Targeting AMR has important clinical implications not only related to diagnosis and management but also prevention of infectious diseases, particularly those causing sepsis.
Determinants of deaths associated with antimicrobial-resistant pathogens known as causative agents of community and hospital-acquired bloodstream infections (BSIs) remain not fully explained. However, in a meta-analysis of sepsis treatment, the mortality rate in patients who were receiving inappropriate antibiotic therapy was higher than among patients who were appropriately treated.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
